Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Duncavage, Eric J; Jacoby, Meagan A; Chang, Gue Su; Miller, Christopher A; Edwin, Natasha; Shao, Jin; Elliott, Kevin; Robinson, Joshua; Abel, Haley; Fulton, Robert S; Fronick, Catrina C; O'Laughlin, Michelle; Heath, Sharon E; Brendel, Kimberly; Saba, Raya; Wartman, Lukas D; Christopher, Matthew J; Pusic, Iskra; Welch, John S; Uy, Geoffrey L; Link, Daniel C; DiPersio, John F; Westervelt, Peter; Ley, Timothy J; Trinkaus, Kathryn; Graubert, Timothy A; Walter, Matthew J.
N Engl J Med
; 379(11): 1028-1041, 2018 09 13.
Artigo em Inglês | MEDLINE | ID: mdl-30207916
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis.
Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.
[Mutation analysis of 77 patients with normal-karyotype myelodysplastic syndrome].